PCI术后前壁心梗患者达标血脂水平与系列CZT-SPECT评估的长期心肌灌注
本研究为回顾性队列研究,纳入462例PCI术后急性前壁心肌梗死患者,按随访期平均血脂水平分为双达标、单达标和未达标三组,用系列静息-负荷CZT-SPECT评估心肌灌注。双达标组12个月MACE发生率更低(8.1% vs 13.3%和22.4%,P=0.001),MPS和LVEF改善最大,双达标为MACE降低的独立预测因素(HR 0.38,P=0.014)。
要点
- 双达标组12个月MACE发生率8.1%,低于单达标组13.3%和未达标组22.4%(P=0.001)。
- 双达标与较低MACE风险独立相关(HR 0.38,P=0.014),校正PCSK9抑制剂使用后仍显著。
- 双达标组MPS改善最大(ΔMPS -5.0 ± 2.1),LVEF改善优于其他组(P<0.001)。
核心结论
- PCI术后达到严格双血脂目标与长期心肌灌注改善、不良重构减轻及MACE发生率降低相关。
- 双达标带来的获益与包括PCSK9抑制剂在内的强化降脂治疗相关,但达标本身仍是改善结局的独立预测因素。
研究设计与样本
- 回顾性队列研究,纳入462例PCI术后急性前壁心肌梗死患者。
- 按随访期平均血脂水平分为双达标组(LDL-C ≤ 1.4 mmol/L且降幅≥ 50%,非HDL-C < 2.2 mmol/L)、单达标组(仅达LDL-C目标)和未达标组。
- 于7天和12个月行regadenoson负荷/静息CZT-SPECT(D-SPECT相机)评估心肌灌注,参数包括MPS、缺血节段数、LVEF和LVEDV,并记录MACE。
主要发现
- 双达标组PCSK9抑制剂使用率66.0%,高于单达标组48.1%和未达标组23.0%(P < 0.001)。
- 12个月时双达标组MACE发生率8.1%,低于单达标组13.3%和未达标组22.4%(P = 0.001),主要驱动因素为心绞痛减少。
- 多因素Cox回归校正PCSK9抑制剂使用后,双达标与较低MACE风险独立相关(HR 0.38,P = 0.014)。
- 纵向随访中双达标组MPS改善最大(ΔMPS -5.0 ± 2.1),LVEF改善优于其他组(P < 0.001)。
关键数值与推荐
- 双达标定义:LDL-C ≤ 1.4 mmol/L且降幅≥ 50%,同时非HDL-C < 2.2 mmol/L。
- 单达标定义:仅达到LDL-C目标。
- 心肌灌注评估时间点为7天和12个月,采用regadenoson负荷/静息CZT-SPECT。
临床怎么用
- PCI术后急性前壁心梗患者应积极追求LDL-C和非HDL-C双达标,以改善长期心肌灌注和预后。
- 双达标与MACE降低独立相关,支持将严格降脂达标作为术后管理的重要目标。
- 系列CZT-SPECT可用于纵向监测心肌灌注和功能变化,辅助评估降脂治疗获益。
局限性
- 本研究为回顾性队列设计。
- 双达标组PCSK9抑制剂使用率显著更高,尽管校正后独立相关仍显著,但治疗强度与达标效果的因果区分受限。
- 原文未报告样本量以外的多中心或盲法设计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the association between achieved lipid levels, as an indicator of lipid residual risk, and longitudinal changes in myocardial perfusion and function in patients with acute anterior myocardial infarction (AMI) after percutaneous coronary intervention (PCI), using serial rest-stress CZT-SPECT imaging. METHODS: In this retrospective cohort study, 462 anterior AMI patients post-PCI were categorized by their mean follow-up lipid levels into three groups: double-target achievement (LDL-C ≤ 1.4 mmol/L and reduction ≥ 50%; non-HDL-C < 2.2 mmol/L), single-target achievement (met LDL-C target only), and non-achievement. Myocardial perfusion was assessed by regadenoson stress/rest CZT-SPECT (D-SPECT camera) at 7 days and 12 months. Parameters included myocardial perfusion score (MPS), ischemic segment count, left ventricular ejection fraction (LVEF), and left ventricular end-diastolic volume (LVEDV). Major adverse cardiovascular events (MACE) were recorded. RESULTS: The double-target group had significantly higher PCSK9 inhibitor use (66.0%) than the single-target (48.1%) and non-achievement groups (23.0%, P < 0.001). At 12 months, this group exhibited a lower MACE incidence (8.1% vs. 13.3% and 22.4%, P = 0.001), driven by reduced angina. Multivariable Cox regression confirmed that double-target achievement was independently associated with lower MACE risk (HR 0.38, P = 0.014) after adjusting for PCSK9 inhibitor use. Longitudinally, the double-target group showed the greatest improvement in MPS (ΔMPS - 5.0 ± 2.1) and LVEF compared to other groups (P < 0.001). CONCLUSION: Achieving stringent dual lipid targets post-PCI is associated with improved long-term myocardial perfusion, attenuated adverse remodeling, and lower MACE incidence. While these benefits are linked to intensive lipid-lowering therapy including PCSK9 inhibitors, achieving lipid targets remains an independent predictor of improved outcomes.
引用
- Chang Y, Li L, Zhou J, et al. Achieved lipid levels and long-term myocardial perfusion assessed by serial CZT-SPECT in post-PCI anterior myocardial infarction. Eur J Nucl Med Mol Imaging. 2026. PMID: 41677812. doi:10.1007/s00259-026-07793-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。